january, 2022

This is a continuing project

Strategic Timing of AntiRetroviral Treatment (START Study) (2012 - 2016)

Project Details

The START study was a cluster site-randomized trial that evaluated a combination intervention package versus the current standard of care with the goal of improving early ART initiation and retention rates during TB treatment, as well as TB treatment success, among HIV-infected TB patients in Lesotho. (funded by PEPFAR through USAID)

View the End-of-Project report here